Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
4Customers
1Debt Items
9Related Chains
Source-Backed Evidence Depth
CERo Therapeutics Holdings, Inc. (CERO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
4Distinct source URLs
5High confidence
0.786Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CERo Therapeutics Holdings, Inc. Suppliers
Ticker
Name
Confidence
Evidence
KEYSTONE-CAPITAL-PARTNERS-LLC
KEYSTONE-CAPITAL-PARTNERS-LLC
92%
On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face val…
SRX-HEALTH-SOLUTIONS-INC
SRX-HEALTH-SOLUTIONS-INC
92%
On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value…
Reciprocal relationship from LPAA graph: Reciprocal relationship from CERO graph: Reciprocal relationship from LPAA graph: tmouth College and a M.B.A. from the Kellogg Graduate School of Management a…
Reciprocal relationship from LPCV graph: Reciprocal relationship from CERO graph: Reciprocal relationship from LPCV graph: ring in October 2024 and is currently searching for a Business Combination t…
CERo Therapeutics Holdings, Inc. Customers
Ticker
Name
Confidence
Evidence
KEYSTONE
KEYSTONE
92%
the Company may sell and issue, and Keystone is obligated to purchase, up to $ 20.6 million of shares of Common Stock
F-K-A-PHOENIX-BIOTECH-ACQUISITION-CORP
F-K-A-PHOENIX-BIOTECH-ACQUISITION-CORP
62%
. This accounting treatment requires that the carrying amount of the embedded derivatives be recorded at fair value on issuance date and marked-to-market at each balance sheet date. On April 27, 2026…
KEYSTONE-CAPITAL-LLC
KEYSTONE-CAPITAL-LLC
62%
from Predecessor to Successor) options and warrants as consideration in the Merger. Asset Acquisition Method of Accounting - The Merger was accounted for using the asset acquisition method in accorda…
SEC-OVERVIEW-CERO-THERAPEUTICS-HOLDINGS-INC
SEC-OVERVIEW-CERO-THERAPEUTICS-HOLDINGS-INC
62%
. This accounting treatment requires that the carrying amount of the embedded derivatives be recorded at fair value on issuance date and marked-to-market at each balance sheet date. On April 27, 2026…
CERo Therapeutics Holdings, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CERO-DEBT-8592
Warrants outstanding: 159724
90%
xbrl warrant detail from xbrl 2026-03-31.
CERo Therapeutics Holdings, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CERo Therapeutics Holdings, Inc..
CERo Therapeutics Holdings, Inc. Ownership
Holder
Name
Confidence
Evidence
CERO-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 2 tracked holders.
CERo Therapeutics Holdings, Inc. Extended Supply Chain Network
